110 related articles for article (PubMed ID: 30643043)
1. [Differential expression of serum miRNAs in patients with advanced non-small cell lung cancer treated by gifitinib before and after acquiring drug resistance].
Huang Q; Li D
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Dec; 43(12):1288-1293. PubMed ID: 30643043
[TBL] [Abstract][Full Text] [Related]
2. Expression Profiles of microRNAs in Drug-Resistant Non-Small Cell Lung Cancer Cell Lines Using microRNA Sequencing.
Hu S; Yuan Y; Song Z; Yan D; Kong X
Cell Physiol Biochem; 2018; 51(6):2509-2522. PubMed ID: 30557872
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.
Hu Y; Qin X; Yan D; Cao H; Zhou L; Fan F; Zang J; Ni J; Xu X; Sha H; Liu S; Yu S; Wu J; Ma R; Feng J
Tumour Biol; 2017 Mar; 39(3):1010428317691659. PubMed ID: 28345454
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.
Ge X; Zheng L; Huang M; Wang Y; Bi F
Mol Med Rep; 2015 Jan; 11(1):333-40. PubMed ID: 25339453
[TBL] [Abstract][Full Text] [Related]
5. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
[TBL] [Abstract][Full Text] [Related]
6. Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.
Sin TK; Wang F; Meng F; Wong SC; Cho WC; Siu PM; Chan LW; Yung BY
Int J Mol Sci; 2016 Feb; 17(2):237. PubMed ID: 26891293
[TBL] [Abstract][Full Text] [Related]
7. Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1).
Rui W; Bing F; Hai-Zhu S; Wei D; Long-Bang C
J Cell Mol Med; 2010 Jan; 14(1-2):206-14. PubMed ID: 19900214
[TBL] [Abstract][Full Text] [Related]
8. miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met.
Cao X; Lai S; Hu F; Li G; Wang G; Luo X; Fu X; Hu J
Sci Rep; 2017 Jun; 7(1):2939. PubMed ID: 28592790
[TBL] [Abstract][Full Text] [Related]
9. miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer.
Hu FY; Cao XN; Xu QZ; Deng Y; Lai SY; Ma J; Hu JB
J Huazhong Univ Sci Technolog Med Sci; 2016 Dec; 36(6):839-845. PubMed ID: 27924500
[TBL] [Abstract][Full Text] [Related]
10. HOXA4-regulated miR-138 suppresses proliferation and gefitinib resistance in non-small cell lung cancer.
Tang X; Jiang J; Zhu J; He N; Tan J
Mol Genet Genomics; 2019 Feb; 294(1):85-93. PubMed ID: 30196354
[TBL] [Abstract][Full Text] [Related]
11. MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer.
Zhong M; Ma X; Sun C; Chen L
Chem Biol Interact; 2010 Mar; 184(3):431-8. PubMed ID: 20097187
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis.
Guo L; Liu Y; Bai Y; Sun Y; Xiao F; Guo Y
Eur J Cancer; 2010 Jun; 46(9):1692-702. PubMed ID: 20371173
[TBL] [Abstract][Full Text] [Related]
13. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.
Sui C; Meng F; Li Y; Jiang Y
J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928
[TBL] [Abstract][Full Text] [Related]
14. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis.
Cao L; Chen J; Ou B; Liu C; Zou Y; Chen Q
Biomed Pharmacother; 2017 Sep; 93():570-579. PubMed ID: 28686971
[TBL] [Abstract][Full Text] [Related]
15. Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small cell lung cancer.
Fan L; Qi H; Teng J; Su B; Chen H; Wang C; Xia Q
Tumour Biol; 2016 Jun; 37(6):7777-84. PubMed ID: 26695145
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer.
Zhen Q; Liu J; Gao L; Liu J; Wang R; Chu W; Zhang Y; Tan G; Zhao X; Lv B
Cytogenet Genome Res; 2015; 146(1):1-8. PubMed ID: 26184032
[TBL] [Abstract][Full Text] [Related]
18. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
19. Aberrant miR-181b-5p and miR-486-5p expression in serum and tissue of non-small cell lung cancer.
Tian F; Shen Y; Chen Z; Li R; Lu J; Ge Q
Gene; 2016 Oct; 591(2):338-43. PubMed ID: 27291819
[TBL] [Abstract][Full Text] [Related]
20. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy.
Wang F; Lou JF; Cao Y; Shi XH; Wang P; Xu J; Xie EF; Xu T; Sun RH; Rao JY; Huang PW; Pan SY; Wang H
Exp Mol Med; 2015 May; 47(5):e162. PubMed ID: 25952770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
